Last updated on December 2019

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Brief description of study

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period.

Clinical Study Identifier: NCT03828747

Find a site near you

Start Over

Butler Hospital; Movement Disorders Program

Providence, RI United States
  Connect »

Rhode Island Mood & Memory Research Institute

East Providence, RI United States
  Connect »